

Gulbake and colleagues present a literature review article which the aim is to colon drug delivery systems as they emphasize in the title of their paper. Such review article is of particular importance because the incidence of disease is increasing and selection of a useful treatment method is of particular interest in colon cancer management.

1. In the manuscript, different delivery methods tabulated in Table 1 and 2. But unfortunately, the authors do not mention clearly to other approaches used for site-specific drug delivery such as; PH and time dependent system, microbial or enzymatically driven drug delivery systems, PH and microflora activated di-dependent systems. Therefore, enough descriptions and details of various delivery systems as well as items shown in the Table 1 are required.

Answer: As per reviewers suggestion different formulation approaches for colon drug delivery have been discussed with explanation.

2. New developed approach for colon-specific drug delivery system like pressure controlled drug delivery systems and osmotic controlled drug delivery system receive no attention in the manuscript.

Answer: As per reviewers suggestion novel drug delivery approaches have been incorporated in the manuscript.

3. In the targeted proapoptotic anticancer drug delivery system section, the drug delivery system is not clear and must be added to the text.

Answer: As per reviewers suggestion drug delivery system has been included in targeted proapoptotic anticancer section.

4. In the immunotherapy section, the authors do not refer to the kind of delivery systems for transferring the bi-specific antibodies and bioengineered DCs cells into the patient's body.

Answer: As this is a review article in which authors have reviewed the previously reported studies. Delivery systems for transferring the bi-specific antibodies and bioengineered DCs cells into the patient's body were not reported by the researchers elsewhere so it is not possible to incorporate the said aspects in the current manuscript.

5. In the gene therapy section, the authors need to mention to the colorectal gene therapy in details not general descriptions. Concomitantly, they must mention to the system delivery of recombinant construct and express drawback related to the delivery of the construct.

Answer: As per reviewer's suggestion colorectal gene therapy has been added in the manuscript.

6. Under the title of manuscript that mention to the drug delivery systems, nutrition supplement therapy section does not communicate with other parts.

Answer: As per reviewers suggestion drug delivery systems have been added in respective parts as



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

much as possible.

7. Abstract section have no informative data related to the drug delivery and must be written again. Also, there is no need to mention to the colorectal cancer etiology and disease stages in this section.

Answer: Abstract has been rewrite and corrected according to revised manuscript.

8. There are typo errors in the text of manuscript that must be corrected by the authors.

Answer: Manuscript has been checked thoroughly and necessary corrections were made.